{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:49:36Z","timestamp":1794649776246,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35-GM159930"],"award-info":[{"award-number":["R35-GM159930"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K08-AR080266"],"award-info":[{"award-number":["K08-AR080266"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32-AR007465"],"award-info":[{"award-number":["T32-AR007465"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32-AR007465"],"award-info":[{"award-number":["T32-AR007465"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41590-026-02548-w","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:04:07Z","timestamp":1782119047000},"page":"1433-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-5586","authenticated-orcid":false,"given":"Caitlin S.","family":"Frazee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-2034","authenticated-orcid":false,"given":"Corbett T.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid A.","family":"Banciella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucianna","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-5033","authenticated-orcid":false,"given":"Jake S.","family":"Fischman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-4099","authenticated-orcid":false,"given":"Chloe L.","family":"Leff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Shestov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5253-0010","authenticated-orcid":false,"given":"Bakir","family":"Valentic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-4544","authenticated-orcid":false,"given":"Roddy S.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-0491","authenticated-orcid":false,"given":"Christoph T.","family":"Ellebrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2548_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"2548_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2548_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531\u2013544 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2548_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2548_CR5","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).","journal-title":"Sci. Transl. Med."},{"key":"2548_CR6","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2548_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2548_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2548_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"2548_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652\u20131663 (2019).","journal-title":"Blood"},{"key":"2548_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"2548_CR12","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1126\/science.1139393","volume":"315","author":"JT Chang","year":"2007","unstructured":"Chang, J. T. et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315, 1687\u20131691 (2007).","journal-title":"Science"},{"key":"2548_CR13","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.4049\/jimmunol.1200176","volume":"188","author":"ML Ciocca","year":"2012","unstructured":"Ciocca, M. L., Barnett, B. E., Burkhardt, J. K., Chang, J. T. & Reiner, S. L. Cutting edge: Asymmetric memory T cell division in response to rechallenge. J. Immunol. 188, 4145\u20134148 (2012).","journal-title":"J. Immunol."},{"key":"2548_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature17442","volume":"532","author":"KC Verbist","year":"2016","unstructured":"Verbist, K. C. et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 532, 389\u2013393 (2016).","journal-title":"Nature"},{"key":"2548_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/ni.3438","volume":"17","author":"KN Pollizzi","year":"2016","unstructured":"Pollizzi, K. N. et al. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation. Nat. Immunol. 17, 704\u2013711 (2016).","journal-title":"Nat. Immunol."},{"key":"2548_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41586-024-07862-7","volume":"633","author":"CS Lee","year":"2024","unstructured":"Lee, C. S. et al. Fate induction in CD8 CAR T cells through asymmetric cell division. Nature 633, 670\u2013677 (2024).","journal-title":"Nature"},{"key":"2548_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther"},{"key":"2548_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct Signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"2548_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"2548_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2548_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"2548_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"2548_CR23","doi-asserted-by":"publisher","unstructured":"Philipson, B. I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci. Signal. https:\/\/doi.org\/10.1126\/scisignal.aay8248 (2020).","DOI":"10.1126\/scisignal.aay8248"},{"key":"2548_CR24","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","volume":"28","author":"AC Boroughs","year":"2020","unstructured":"Boroughs, A. C. et al. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq. Mol. Ther. 28, 2577\u20132592 (2020).","journal-title":"Mol. Ther."},{"key":"2548_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nature25442","volume":"553","author":"G Pasqual","year":"2018","unstructured":"Pasqual, G. et al. Monitoring T cell\u2013dendritic cell interactions in vivo by intercellular enzymatic labelling. Nature 553, 496\u2013500 (2018).","journal-title":"Nature"},{"key":"2548_CR26","doi-asserted-by":"publisher","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.96976 (2018).","DOI":"10.1172\/jci.insight.96976"},{"key":"2548_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong, W. et al. Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol. Ther. 26, 963\u2013975 (2018).","journal-title":"Mol. Ther"},{"key":"2548_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 21, 17\u201326 (2017).","journal-title":"Cell Rep."},{"key":"2548_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-024-07134-4","volume":"627","author":"S Nakandakari-Higa","year":"2024","unstructured":"Nakandakari-Higa, S. et al. Universal recording of immune cell interactions in vivo. Nature 627, 399\u2013406 (2024).","journal-title":"Nature"},{"key":"2548_CR30","first-page":"15.13.11","volume":"15","author":"MW Popp","year":"2009","unstructured":"Popp, M. W., Antos, J. M. & Ploegh, H. L. Site-specific protein labeling via sortase-mediated transpeptidation. Curr. Protoc. Protein Sci. 15, 15.13.11\u201315.13.19 (2009).","journal-title":"Curr. Protoc. Protein Sci."},{"key":"2548_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41586-022-04849-0","volume":"607","author":"A Guo","year":"2022","unstructured":"Guo, A. et al. cBAF complex components and MYC cooperate early in CD8+ T cell fate. Nature 607, 135\u2013141 (2022).","journal-title":"Nature"},{"key":"2548_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"2548_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh3113","volume":"8","author":"JG Silva","year":"2023","unstructured":"Silva, J. G. et al. Emergence and fate of stem cell-like Tcf7+ CD8+ T cells during a primary immune response to viral infection. Sci. Immunol. 8, eadh3113 (2023).","journal-title":"Sci. Immunol."},{"key":"2548_CR34","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.molcel.2022.04.016","volume":"82","author":"S Liedmann","year":"2022","unstructured":"Liedmann, S. et al. Localization of a TORC1-eIF4F translation complex during CD8+ T cell activation drives divergent cell fate. Mol. Cell 82, 2401\u20132414 (2022).","journal-title":"Mol. Cell"},{"key":"2548_CR35","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.4049\/jimmunol.1400930","volume":"193","author":"D Avram","year":"2014","unstructured":"Avram, D. & Califano, D. The multifaceted roles of Bcl11b in thymic and peripheral T cells: impact on immune diseases. J Immunol 193, 2059\u20132065 (2014).","journal-title":"J Immunol"},{"key":"2548_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","volume":"37","author":"C Sun","year":"2020","unstructured":"Sun, C. et al. THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells. Cancer Cell 37, 216\u2013225 (2020).","journal-title":"Cancer Cell"},{"key":"2548_CR37","doi-asserted-by":"publisher","unstructured":"Wu, L. et al. Difference in efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy containing 4-1BB and CD28 co-stimulatory domains for B-cell acute lymphoblastic leukemia. Cancers https:\/\/doi.org\/10.3390\/cancers15102767 (2023).","DOI":"10.3390\/cancers15102767"},{"key":"2548_CR38","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1016\/j.jtct.2024.01.074","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann, N. et al. Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis. Transplant. Cell Ther. 30, e581\u2013e584 (2024).","journal-title":"Transplant. Cell Ther."},{"key":"2548_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41409-026-02803-6","volume":"61","author":"V Navarro","year":"2026","unstructured":"Navarro, V. et al. CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Bone Marrow Transplant. 61, 452\u2013461 (2026).","journal-title":"Bone Marrow Transplant."},{"key":"2548_CR40","first-page":"3153","volume":"141","author":"ME Selli","year":"2023","unstructured":"Selli, M. E. et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood 141, 3153\u20133165 (2023).","journal-title":"Blood"},{"key":"2548_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"2548_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"2548_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"MD Buck","year":"2016","unstructured":"Buck, M. D. et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166, 63\u201376 (2016).","journal-title":"Cell"},{"key":"2548_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn0484","volume":"8","author":"EY Helm","year":"2023","unstructured":"Helm, E. Y. et al. Bcl11b sustains multipotency and restricts effector programs of intestinal-resident memory CD8+ T cells. Sci. Immunol. 8, eabn0484 (2023).","journal-title":"Sci. Immunol."},{"key":"2548_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.immuni.2023.03.017","volume":"56","author":"S Quon","year":"2023","unstructured":"Quon, S. et al. DNA architectural protein CTCF facilitates subset-specific chromatin interactions to limit the formation of memory CD8+ T cells. Immunity 56, 959\u2013978 (2023).","journal-title":"Immunity"},{"key":"2548_CR46","doi-asserted-by":"publisher","first-page":"836549","DOI":"10.3389\/fimmu.2022.836549","volume":"13","author":"L Halim","year":"2022","unstructured":"Halim, L. et al. Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4-1BB co-stimulation. Front. Immunol. 13, 836549 (2022).","journal-title":"Front. Immunol."},{"key":"2548_CR47","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"2548_CR48","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari, B. et al. Epigenetic strategies to boost CAR T cell therapy. Mol. Ther. 29, 2640\u20132659 (2021).","journal-title":"Mol. Ther."},{"key":"2548_CR49","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao, Y. et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70, 9053\u20139061 (2010).","journal-title":"Cancer Res."},{"key":"2548_CR50","doi-asserted-by":"publisher","first-page":"W398","DOI":"10.1093\/nar\/gkae253","volume":"52","author":"Z Pang","year":"2024","unstructured":"Pang, Z. et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res. 52, W398\u2013W406 (2024).","journal-title":"Nucleic Acids Res."},{"key":"2548_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"2548_CR52","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1093\/bioinformatics\/btaa1009","volume":"36","author":"C Ahlmann-Eltze","year":"2020","unstructured":"Ahlmann-Eltze, C. & Huber, W. glmGamPoi: fitting Gamma-Poisson generalized linear models on single cell count data. Bioinformatics 36, 5701\u20135702 (2020).","journal-title":"Bioinformatics"},{"key":"2548_CR53","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","volume":"38","author":"V Bergen","year":"2020","unstructured":"Bergen, V., Lange, M., Peidli, S., Wolf, F. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. 38, 1408\u20131414 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2548_CR54","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41592-021-01282-5","volume":"18","author":"T Stuart","year":"2021","unstructured":"Stuart, T., Srivastava, A., Madad, S., Lareau, C. A. & Satija, R. Single-cell chromatin state analysis with Signac. Nat. Methods 18, 1333\u20131341 (2021).","journal-title":"Nat. Methods"},{"key":"2548_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2548_CR56","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41592-023-01938-4","volume":"20","author":"C Bravo Gonz\u00e1lez-Blas","year":"2023","unstructured":"Bravo Gonz\u00e1lez-Blas, C. et al. SCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks. Nat. Methods 20, 1355\u20131367 (2023).","journal-title":"Nat. Methods"},{"key":"2548_CR57","doi-asserted-by":"crossref","unstructured":"Stoeckius, M. CITE-seq Protocol (New York Genome Center, 2019); https:\/\/citeseq.wordpress.com\/wp-content\/uploads\/2019\/02\/cite-seq_190213.pdf","DOI":"10.17504\/protocols.io.ngydbxw"},{"key":"2548_CR58","doi-asserted-by":"publisher","unstructured":"Corbett, B. Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor co-stimulatory domains. Zenodo https:\/\/doi.org\/10.5281\/zenodo.15706889 (2025).","DOI":"10.5281\/zenodo.15706889"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02548-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02548-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02548-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:02:54Z","timestamp":1782684174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02548-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1038\/s41590-026-02548-w","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T.E. has equity (Cabaletta Bio) and patent licensing (Cabaletta Bio and Novartis). R.O.C. has equity (Nucleus Biologics), a research grant (NeoTx) and patent licensing (Novartis). M.C.M. has equity (Cabaletta Bio and Verismo), a research grant (Cabaletta Bio) and patent licensing (Cabaletta Bio, Novartis and Tmunity Therapeutics, Verismo) and has received payment (Cabaletta Bio). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}